VentiRx Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- VentiRx Pharmaceuticals's estimated annual revenue is currently $2M per year.
- VentiRx Pharmaceuticals's estimated revenue per employee is $155,000
Employee Data
- VentiRx Pharmaceuticals has 13 Employees.
- VentiRx Pharmaceuticals grew their employee count by -19% last year.
VentiRx Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|
VentiRx Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $8.7M | 56 | 2% | N/A | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $5.7M | 37 | -33% | N/A | N/A |
#4 | $114.8M | 529 | 6% | N/A | N/A |
#5 | $0.8M | 5 | 0% | N/A | N/A |
#6 | $0.6M | 4 | 0% | N/A | N/A |
#7 | $14.7M | 83 | -22% | $206.4M | N/A |
#8 | $492.2M | 1834 | -15% | $568M | N/A |
#9 | $1.9M | 12 | 71% | N/A | N/A |
#10 | $4.8M | 31 | 7% | N/A | N/A |
What Is VentiRx Pharmaceuticals?
VentiRx is a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases. VentiRx has a broad clinical pipeline. The lead clinical oncology asset, VTX-2337, is a small molecule TLR8 agonist, currently in multiple clinical trials in combination with chemotherapies and monoclonal antibodies. The company has entered into a worldwide strategic collaboration with Celgene Corporation for this program.
keywords:N/A
N/A
Total Funding
13
Number of Employees
$2M
Revenue (est)
-19%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Summit
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.6M | 13 | -19% | N/A |
#2 | N/A | 13 | 0% | N/A |
#3 | $1.8M | 14 | 0% | N/A |
#4 | $3.5M | 15 | -57% | N/A |
#5 | $3.3M | 17 | -6% | N/A |